Kexing Biopharm’s overseas commercial product, Albumin-bound Paclitaxel, has been approved for marketing in the Philippines.

Article source：Apr 19,2026View： 197

Recently, Kexing Biopharm announced that its overseas drug—Paclitaxel for Injection (Albumin-bound) (brand name: Apexelsin®)—has received marketing approval from the Philippine Food and Drug Administration.

Compared with conventional paclitaxel injections and liposomal paclitaxel formulations, albumin-bound paclitaxel offers notable clinical advantages, including improved safety and better patient compliance. It has gained strong clinical recognition and holds indispensable value in the field of oncology treatment.

As a key pharmaceutical market in Southeast Asia, the Philippines has seen a growing demand in recent years for high-quality medicines. The approval of Apexelsin® will provide local cancer patients with a new treatment option.

Since obtaining marketing authorization in the European Union in 2024, Apexelsin® has continued to accelerate its global commercialization. Over the past two years, it has been approved in multiple countries and regions, including the United Kingdom, Peru, Uruguay, Argentina, Oman, Malaysia, and Macao, China, forming a global sales network spanning the EU, Latin America, Southeast Asia, and the Middle East.

Looking ahead, Kexing Biopharm will continue to collaborate with more partners to enhance global accessibility to high-quality medicines.